早期周围型肺癌立体定向体部放疗后肿瘤乏氧与再氧合的可视化:一项前瞻性研究
前瞻性纳入15例T1-2 N0肺癌患者,SBRT处方剂量48-52 Gy分4次,首次照射后1-3天行F-MISO PET/CT评估乏氧与再氧合。治疗前9个肿瘤(60%)存在乏氧,单次高剂量照射后乏氧肿瘤TMR下降提示再氧合,F-MISO摄取似乎是不良预后因素。
要点
- 15例早期肺癌SBRT,治疗前60%(9/15)肿瘤存在乏氧(TMR≥1.30)。
- 单次高剂量照射后,9个乏氧肿瘤中6个TMR下降,提示再氧合。
- 无预处理乏氧的6个肿瘤TMR在照射后均升高。
核心结论
- 单次高剂量照射后肿瘤乏氧降低。
- F-MISO摄取的肿瘤似乎是肺SBRT的不良预后因素。
研究设计与样本
- 前瞻性研究,纳入T1-2 N0肺癌患者15例,2016年至2021年。
- SBRT处方剂量48-52 Gy分4次。
- 于SBRT前及首次照射后1-3天各行一次F-MISO PET/CT,以SUVmax和肿瘤/肌肉比值(TMR)评估乏氧,乏氧阈值定义为TMR≥1.30。
主要发现
- 治疗前9个肿瘤(60%)存在乏氧。
- 6个无预处理乏氧的肿瘤在单次高剂量照射后TMR均升高。
- 9个有预处理乏氧的肿瘤中6个在照射后TMR下降,提示再氧合。
- 无局部复发,但4例患者(27%)出现区域和/或远处复发,其中3例为F-MISO摄取异常的肿瘤,另1例治疗前PET/CT无乏氧征象。
- 有和无预处理乏氧患者的2年无进展生存率分别为30%和63%(p=0.319)。
关键数值与推荐
- 乏氧判定阈值:TMR≥1.30。
- 处方剂量:48-52 Gy分4次。
- F-MISO PET/CT评估时间点:SBRT前及首次照射后1-3天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: In this study, fluoromisonidazole positron emission tomography (F-MISO PET/CT) was used to evaluate tumor hypoxia and re-oxygenation in patients with lung tumors treated with stereotactic body radiation therapy (SBRT). MATERIALS AND METHODS: Patients with T1-2 N0 lung cancer were included in this study. The prescribed dose was 48-52 Gy in four fractions. F-MISO PET/CT was performed twice, before SBRT and 1-3 days after the first irradiation. The maximum standardized uptake value (SUVmax) and tumor/muscle ratio (TMR) were evaluated as indicators of hypoxia. The threshold for hypoxia was defined as a TMR of 1.30 or more. RESULTS: Between 2016 and 2021, 15 patients were included. Pre-treatment tumor hypoxia was observed in nine tumors (60 %). TMR in all six tumors without pre-treatment hypoxia rose after single high-dose irradiation. In contrast, TMR in six of nine tumors with pre-treatment hypoxia dropped after irradiation, suggesting re-oxygenation. Although no local recurrence was noted, regional and/or distant relapses were seen in four patients (27 %). Of these, three had tumors with abnormal F-MISO uptake. The remaining patient had a tumor without signs of hypoxia on pre-treatment PET/CT. The 2-year progression free survival of patients with tumors with and without pre-treatment hypoxia were 30 % and 63 %, respectively (p = 0.319). CONCLUSION: Tumor hypoxia reduced after single high-dose irradiation. Tumor with F-MISO uptake seems to be an unfavorable prognostic factor in lung SBRT.
引用
- Inada M, Nishimura Y, Hanaoka K, et al. Visualization of tumor hypoxia and re-oxygenation after stereotactic body radiation therapy in early peripheral lung cancer: A prospective study. Radiother Oncol. 2023. PMID: 36706956. doi:10.1016/j.radonc.2023.109491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。